The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate (Paricalcitol)
|ClinicalTrials.gov Identifier: NCT01163162|
Recruitment Status : Completed
First Posted : July 15, 2010
Results First Posted : May 21, 2013
Last Update Posted : May 21, 2013
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Disease||Drug: Paricalcitol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||March 2011|
|Actual Study Completion Date :||June 2011|
After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
2 mcg oral Paricalcitol once per day for 7 days
Other Name: Zemplar
- 24-hour Urine Creatinine Excretion Rate [ Time Frame: 1 Week ]We expect the 24 hour urine creatinine excretion rate to show no differences between groups.
- Creatinine Clearance [ Time Frame: 1 Week ]The primary outcome variable will be creatinine clearance. Subject will be used as random variable and maximal likelihood estimation methods will be used. We expect no differences between periods.
- Serum Creatinine [ Time Frame: 1 Week ]We expect serum creatinine to confirm the results of creatinine clearance.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01163162
|United States, Indiana|
|Roudebush VA Medical Center|
|Indianapolis, Indiana, United States, 46202|
|Principal Investigator:||Rajiv Agarwal, MD||Indiana University|